Interview with VP and Co-Founder of Bright Minds Biosciences, Dr. Gideon Shapiro, Ph.D.

Bright Minds Biosciences is a Canadian Stock Exchange listed biotech company dedicated to developing next-generation therapeutics to improve the lives of patients with severe and life-altering brain diseases.  The company’s broad portfolio of new molecular entities (NCEs) are positioned to treat a variety of pain indications, seizures, and neuropsychiatric disorders. By leveraging the extensive drug discovery experience of the team, Bright Minds Biosciences is creating a pipeline of best-in-class 5-HT (serotonin) medicines. Their patented lead drug candidates feature next generation characteristics, reducing unwanted side effects and maximizing therapeutic attributes. Bright Minds Biosciences’ compounds are targeted therapies that allow for the treatment of specific patient populations.